Zubsolv

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
10-10-2023
Produktens egenskaper Produktens egenskaper (SPC)
10-10-2023

Aktiva substanser:

Buprenorphine hydrochloride, Naloxone hydrochloride dihydrate

Tillgänglig från:

Accord Healthcare S.L.U.

ATC-kod:

N07BC51

INN (International namn):

buprenorphine, naloxone

Terapeutisk grupp:

Other nervous system drugs

Terapiområde:

Opioid-Related Disorders

Terapeutiska indikationer:

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Produktsammanfattning:

Revision: 10

Bemyndigande status:

Authorised

Tillstånd datum:

2017-11-10

Bipacksedel

                                48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ZUBSOLV 0.7 MG/0.18 MG SUBLINGUAL TABLETS
ZUBSOLV 1.4 MG/0.36 MG SUBLINGUAL TABLETS
ZUBSOLV 2.9 MG/0.71 MG SUBLINGUAL TABLETS
ZUBSOLV 5.7 MG/1.4 MG SUBLINGUAL TABLETS
ZUBSOLV 8.6 MG/2.1 MG SUBLINGUAL TABLETS
ZUBSOLV 11.4 MG/2.9 MG SUBLINGUAL TABLETS
buprenorphine/naloxone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Zubsolv is and what it is used for
2.
What you need to know before you take Zubsolv
3.
How to take Zubsolv
4.
Possible side effects
5.
How to store Zubsolv
6.
Contents of the pack and other information
1.
WHAT ZUBSOLV IS AND WHAT IT IS USED FOR
Zubsolv contains the active substances buprenorphine and naloxone.
Zubsolv is used to treat
dependence on opioid (narcotic) drugs such as heroin or morphine in
drug addicts who have agreed
to be treated for their addiction. Zubsolv is used in adults and
adolescents over 15 years of age,
who are also receiving medical, social and psychological support.
HOW ZUBSOLV WORKS
The tablet contains buprenorphine which is responsible for the
treatment of opioid (narcotic)
dependence. It also contains naloxone which is used to deter
intravenous abuse of the product.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZUBSOLV
DO NOT TAKE ZUBSOLV
IF YOU:
-
are allergic to buprenorphine, naloxone or any of the other
ingredients of this medicine
(listed in section 6)
-
have SERIOUS BREATHING PROBLEMS
-
have
SERIOUS LIVER PROBLEMS
-
are intoxicated due to alcohol or have trembling, sweating, anxiety
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Zubsolv 0.7 mg/0.18 mg sublingual tablets
Zubsolv 1.4 mg/0.36 mg sublingual tablets
Zubsolv 2.9 mg/0.71 mg sublingual tablets
Zubsolv 5.7 mg/1.4 mg sublingual tablets
Zubsolv 8.6 mg/2.1 mg sublingual tablets
Zubsolv 11.4 mg/2.9 mg sublingual tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Zubsolv 0.7 mg/0.18 mg sublingual tablets
Each 0.7 mg/0.18 mg sublingual tablet contains 0.7 mg buprenorphine
(as hydrochloride) and
0.18 mg naloxone (as hydrochloride dihydrate).
Zubsolv 1.4 mg/0.36 mg sublingual tablets
Each 1.4 mg/0.36 mg sublingual tablet contains 1.4 mg buprenorphine
(as hydrochloride) and
0.36 mg naloxone (as hydrochloride dihydrate).
Zubsolv 2.9 mg/0.71 mg sublingual tablets
Each 2.9 mg/0.71 mg sublingual tablet contains 2.9 mg buprenorphine
(as hydrochloride) and
0.71 mg naloxone (as hydrochloride dihydrate).
Zubsolv 5.7 mg/1.4 mg sublingual tablets
Each 5.7 mg/1.4 mg sublingual tablet contains 5.7 mg buprenorphine (as
hydrochloride) and 1.4 mg
naloxone (as hydrochloride dihydrate).
Zubsolv 8.6 mg/2.1 mg sublingual tablets
Each 8.6 mg/2.1 mg sublingual tablet contains 8.6 mg buprenorphine (as
hydrochloride) and 2.1 mg
naloxone (as hydrochloride dihydrate).
Zubsolv 11.4 mg/2.9 mg sublingual tablets
Each 11.4 mg/2.9 mg sublingual tablet contains 11.4 mg buprenorphine
(as hydrochloride) and
2.9 mg naloxone (as hydrochloride dihydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Sublingual tablet
Zubsolv 0.7 mg/0.18 mg sublingual tablets
A white to off-white, oval tablet, length 6.8 mm and width 4.0 mm,
debossed with “.7” on one side.
Zubsolv 1.4 mg/0.36 mg sublingual tablets
A white to off-white, triangular tablet, base 7.2 mm and height 6.9
mm, debossed with “1.4” on one
3
side.
Zubsolv 2.9 mg/0.71 mg sublingual tablets
A white to off-white, D-shaped tablet, height 7.3 mm and width 5.65
mm, debossed with “2.9” on
one side.
Zubsolv 5.7 mg/1.4 mg sublingual tablets
A white to off-whit
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 10-10-2023
Produktens egenskaper Produktens egenskaper bulgariska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 12-01-2018
Bipacksedel Bipacksedel spanska 10-10-2023
Produktens egenskaper Produktens egenskaper spanska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 12-01-2018
Bipacksedel Bipacksedel tjeckiska 10-10-2023
Produktens egenskaper Produktens egenskaper tjeckiska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 12-01-2018
Bipacksedel Bipacksedel danska 10-10-2023
Produktens egenskaper Produktens egenskaper danska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 12-01-2018
Bipacksedel Bipacksedel tyska 10-10-2023
Produktens egenskaper Produktens egenskaper tyska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 12-01-2018
Bipacksedel Bipacksedel estniska 10-10-2023
Produktens egenskaper Produktens egenskaper estniska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 12-01-2018
Bipacksedel Bipacksedel grekiska 10-10-2023
Produktens egenskaper Produktens egenskaper grekiska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 12-01-2018
Bipacksedel Bipacksedel franska 10-10-2023
Produktens egenskaper Produktens egenskaper franska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 12-01-2018
Bipacksedel Bipacksedel italienska 10-10-2023
Produktens egenskaper Produktens egenskaper italienska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 12-01-2018
Bipacksedel Bipacksedel lettiska 10-10-2023
Produktens egenskaper Produktens egenskaper lettiska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 12-01-2018
Bipacksedel Bipacksedel litauiska 10-10-2023
Produktens egenskaper Produktens egenskaper litauiska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 12-01-2018
Bipacksedel Bipacksedel ungerska 10-10-2023
Produktens egenskaper Produktens egenskaper ungerska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 12-01-2018
Bipacksedel Bipacksedel maltesiska 10-10-2023
Produktens egenskaper Produktens egenskaper maltesiska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 12-01-2018
Bipacksedel Bipacksedel nederländska 10-10-2023
Produktens egenskaper Produktens egenskaper nederländska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 12-01-2018
Bipacksedel Bipacksedel polska 10-10-2023
Produktens egenskaper Produktens egenskaper polska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 12-01-2018
Bipacksedel Bipacksedel portugisiska 10-10-2023
Produktens egenskaper Produktens egenskaper portugisiska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 12-01-2018
Bipacksedel Bipacksedel rumänska 10-10-2023
Produktens egenskaper Produktens egenskaper rumänska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 12-01-2018
Bipacksedel Bipacksedel slovakiska 10-10-2023
Produktens egenskaper Produktens egenskaper slovakiska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 12-01-2018
Bipacksedel Bipacksedel slovenska 10-10-2023
Produktens egenskaper Produktens egenskaper slovenska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 12-01-2018
Bipacksedel Bipacksedel finska 10-10-2023
Produktens egenskaper Produktens egenskaper finska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 12-01-2018
Bipacksedel Bipacksedel svenska 10-10-2023
Produktens egenskaper Produktens egenskaper svenska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 12-01-2018
Bipacksedel Bipacksedel norska 10-10-2023
Produktens egenskaper Produktens egenskaper norska 10-10-2023
Bipacksedel Bipacksedel isländska 10-10-2023
Produktens egenskaper Produktens egenskaper isländska 10-10-2023
Bipacksedel Bipacksedel kroatiska 10-10-2023
Produktens egenskaper Produktens egenskaper kroatiska 10-10-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 12-01-2018

Visa dokumenthistorik